Discover more from FarmaKology’s Substack
FarmaKology Newsletter - Issue #21
HeartFlow is a medical technology company transforming the way cardiovascular disease is diagnosed and treated. With our HeartFlow Analysis, a non-invasive personalized cardiac test, physicians are able to make better care decisions for their patients with suspected coronary artery disease--the number one killer of men and women worldwide. HeartFlow is backed by decades of scientific research and development and leverages the latest advancements in technology to help set a new standard of care for diagnosing cardiovascular care worldwide.
Lilly's REYVOW™ (lasmiditan), The First and Only Medicine in a New Class of Acute Treatment for Migraine, Receives FDA Approval
Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved REYVOW™ (lasmiditan) an oral medication for the acute treatment of migraine, with or without aura, in adults. REYVOW has a unique mechanism of action and is the first and only FDA-approved medicine in a new class of acute treatment for migraine (serotonin (5-HT)1F receptor agonists).
China will strengthen monitoring of the supply and prices of drugs in shortage, according to a guideline issued by the General Office of the State Council.The guideline said a supply monitoring mechanism will be established to enhance coordination between multiple information platforms, noting the information concerning the registration, production, procurement and prices of the drugs raw materials will be shared through the mechanism.
The U.S. Department of Health and Human Services published a new Guide for Clinicians on the Appropriate Dosage Reduction or Discontinuation of Long-Term Opioid Analgesics. Individual patients, as well as the health of the public, benefit when opioids are prescribed only when the benefit of using opioids outweighs the risks.
Aclaris Therapeutics Inc., a Chester County biopharmaceutical company that last month unveiled a new strategy to focus, has sold a medicine used to treat rosacea in a deal valued at up to $55 million.